References
1. Kasahara M, Umeshita K, Inomata Y, et al. Long-term outcomes of
pediatric living donor liver transplantation in Japan analysis of more
than 2200 cases listed in the registry of the Japanese Liver
Transplantation Society[J]. Am J Transplant 2013;13:1830-1839.
2. Lauro A, Arpinati M, Pinna AD. Managing the challenge of PTLD in
liver and bowel transplant recipients[J]. Br J Haematol
2014;169:157-172.
3. Kumarasinghe G, Lavee O, Parker A, et al. Post-transplant
lymphoproliferative disease in heart and lung transplantation: Defining
risk and prognostic factors[J]. J Heart Lung Transplant
2015;34:1406-1414.
4. Martin M, Tilmann S, Uta B, et al. Posttransplant lymphoproliferative
disease after pediatric solid organ transplantation[J]. Clin Dev
Immunol 2013;(2013):1-14.
5. Jeong HJ, Ahn YH, Park E, et al. Posttransplantation
lymphoproliferative disorder after pediatric solid organ
transplantation: Experiences of 20 years in a single center[J].
Korean J Pediatr 2017;60:86-93.
6. Ruf S,
Behnke-Hall
K, Gruhn
B, et al. Comparison of six different specimen types for Epstein-Barr
viral load quantification in peripheral blood of pediatric patients
after heart transplantation or after allogeneic hematopoietic stem cell
transplantation [J]. Clin Virol 2012;53:186-194.
7. Schubert S, Renner C, Hammer M, et al. Relationship of
immunosuppression to Epstein–Barr viral load and lymphoproliferative
disease in pediatric heart transplant patients[J]. J Heart Lung
Transplant 2008;27:0-105.
8. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant
lymphoproliferative disorder in solid organ transplant recipients—BCSH
and BTS guidelines. Br J Haematol 2010;149:675-692.
9. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant
lymphoproliferative disorders: risk, classification, and therapeutic
recommendations. Curr Treat Options in Oncol 2012;13:122-136.
10. Chinnock R, Webber SA, Dipchand AI, et al. A 16-Year
multi-institutional study of the role of age and EBV Status on PTLD
incidence among pediatric heart transplant recipients[J]. American J
Transplant 2012;12:3061-3068.
11. Dolcetti R. B lymphocytes and Epstein–Barr virus: The lesson of
post-transplant lymphoproliferative disorders[J]. Autoimmun Rev
2008;7:96-101.
12. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on[J]. Nat
Rev Cancer 2004;4:757-768.
13. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus
(EBV) load: the significance and application for each EBV-associated
disease [J]. Rev Med Virol 2008;18:305-319.
14. Kalra A,Roessner C,Jupp J,et al. Epstein-bar virus DNA-emia
monitoring for the management of post- transplant lymphoproliferative
disorder [J]. Cytotherapy 2018;20:706-714.
15. Kim JM, Lee SK, Kim SJ, et al. Risk factors for posttransplant
lymphoproliferative disorder in pediatric liver transplant recipients
with cytomegalovirus antigenemia[J]. Transplant Proc 2010;42:0-899.
16. Cockfield SM. Identifying the patient at risk for post-transplant
lymphoproliferative disorder[J]. Transpl Infect Dis 2001;3:70-78.
17. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant
lymphoproliferative disorders: risk, classification, and therapeutic
recommendations. Curr Treat Options in Oncol 2012;13:122–136.
18. Fukushima D, Sato K, Kawagishi N, et al. Epstein-Barr
virus—associated posttransplantation lymphoproliferative disorder with
tacrolimus metabolism deterioration in infants after living-donor liver
transplantation[J]. Transplantation 2015;99:114-119.
19. Lu BR, Park KT, Hurwitz M, et al. Impact of immunosuppression on the
development of Epstein-Barr virus (EBV) viremia after pediatric liver
transplantation[J]. Transplant Proc 2013;45:301-304.
20. Bakker NA, Verschuuren EAM, Erasmus ME, et al. Epstein-Barr
virus-DNA load monitoring late after lung transplantation: a surrogate
marker of the degree of immunosuppression and a safe guide to reduce
immunosuppression [J]. Transplantation 2007;83:433-438.
21. Cosmas D, Wimmer, Martin K, et al. Impact of cyclosporine versus
tacrolimus on the incidence of de novo malignancy following liver
transplantation: a single center experience with 609 patients [J].
Transpl Int 2013;26:999-1006.
22. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative
disorders (PTLD) after solid organ transplantation[J]. Crit Rev
Oncol Hematol 2005;56:155-167.
23. Chinnock R, Webber SA, Dipchand AI et al. A 16-Year
multi-institutional study of the role of age and EBV Status on PTLD
incidence among pediatric heart transplant recipients[J]. Am J
Transplant 2012;12:3061-3068.
24. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk
factors for Epstein-Barr virus-associated posttransplant
lymphoproliferative disorder in pediatric liver transplant recipients
using objective case ascertainment[J]. Transplantation
2003;75:987-993.
25. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection
and infection in pediatric liver transplantation[J]. Am J Transplant
2008;8:396-403.